A Study to Evaluate Safety and Tolerability in Patients With Metastatic Breast Cancer Receiving Treatment With Caelyx (Study P04878)(COMPLETED)

Merck Sharp & Dohme (MSD)

Status: Completed

Conditions: Breast Neoplasm

Treatments: Drug: Pegylated Liposomal Doxorubicin

Study type: Observational

Funder types: Industry

Identifiers

NCT00736333

P04878

Details and patient eligibility

About

This is a study to evaluate the safety and tolerability of Caelyx used for the treatment of metastatic breast cancer (MBC), focusing on infusion reaction and palmar-plantar erythrodysesthesia (PPE).

Full description

Patients selected by investigator according to clinical routine

Enrollment: 167 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with metastatic breast cancer

Exclusion criteria

• History of hypersensitivity to Caelyx or its components
• Women who are pregnant or breast-feeding
• Patients with severe myelosuppression

Trial design

167 participants in 1 patient group

Pegylated Liposomal Doxorubicin

Description:

Subjects with metastatic breast cancer

Treatment:

Drug: Pegylated Liposomal Doxorubicin